Chronic Lower Back Pain Market Size is Expected to Increase With a CAGR of 3.55% for the Study Period, 2017-2030 in the 7MM

LAS VEGAS, May 12, 2020 /PRNewswire/ -- DelveInsight added a new report titled Chronic Lower Back Pain (CLBP) Market Insights, Epidemiology and Market Forecast–2030 to its portfolio.

Few highlights:

• Chronic Lower Back Pain Market landscape involves 15+ companies actively working in advancing CLBP market.
• Of the emerging therapies, Braeburn Pharmaceuticals/Camurus, Pfizer/Eli Lilly and Company, Mesoblast, Egalet Corporation are expected to launch their respective products, during the forecast period.
• The current CLBP market size is entirely dominated by on supportive treatment regimens along with the drugs that have been approved to treat comorbidities associated with CLBP, and those that are approved for chronic pain usually.
• The current opioid prescription market is expected to decline in the coming years because CLBP patients will switch from currently prescribed opioids to emerging opioid therapies, such as Buprenorphine and Egalet‐002.
• Limited Chronic Lower Back Pain treatment options are the major market driving forces in the CLBP market.

Request a sample page: https://www.delveinsight.com/sample-request/chronic-lower-back-pain-clbp-market

Lower back pain is a common ailment, and at everyone at a certain point of time must have felt it. However, if the pain persists for more than 3-months, it is referred to as chronic lower back pain and is the second leading cause of the disability and degraded quality of life worldwide. The origin, as well as the intensity of the pain, may vary from an injury, disease to stress and from mild to severe.

Chronic Lower Back Pain Epidemiology

According to DelveInsight's analysis, the total CLBP prevalent population in the 7MM was observed to be 73,802,461 in 2017, which is expected to increase during the study period, i.e., 2017–2030. A higher percentage of diagnosed prevalence was observed for females in comparison to males, in all the 7MM countries, except Japan, wherein males occupy a larger patient pool than females. Also it has been observed that CLBP is mostly diagnosed in the age group of 40–69.

The report offers disease epidemiology in the 7MM for the study period 2017 to 2030 segmented by:

• Total Prevalent Population of Chronic Lower Back Pain
• Total Diagnosed Prevalent Population of Chronic Lower Back Pain
• Gender-Specific Diagnosed Prevalence of Chronic Lower Back Pain
• Age-Specific Diagnosed Prevalence of Chronic Lower Back Pain
• Severity Specific Diagnosed Prevalence of Chronic Lower Back Pain
• Number of CLBP Patients on Prescription Medications by different Class
• Number of CLBP Patients on Opioids by low dose, high dose and Overdose scenario

Present therapies in the CLBP market only provide temporary relief from the pain. At present the Chronic Lower Back Pain market is dominated by opioids. However, the long-term opioid use results in addiction, hence the current scenario demands products with better safety profile and improved Quality of Life (QoL).

The report offers an exhaustive coverage of the marketed as well as the emerging drugs.

Marketed Drugs

• Cymbalta: Eli Lilly and Company
• Xtampa: Collegium Pharmaceutical
• Butrans: Purdue Pharma
• Belbuca: BioDelivery Sciences International
  And many others

In the pipeline

• Tanezumab: Eli Lilly/Pfizer
• Fasinumab: Regeneron Pharmaceuticals/ Teva Pharmaceuticals
• MPC-06-ID: Mesoblast
• Egalet‐002 (Egalet Corporation)
• AXS‐02 (Axsome Therapeutics)
• ALLOD‐2 (Allodynic Therapeutics)
• ASP7962 (Astellas Pharma)
• CAM2038 (Braeburn Pharmaceuticals/Camurus)
• Clonidine Micropellets (Sollis Therapeutics)
• NKTR‐181 (Nektar Therapeutics)
• GRT6005: Grünenthal GmbH
• AB001: Frontier Biotechnologies
• IDCT (DiscGenics)
• YH14618 (Yuhan Corporation)
• SP‐102 (Semnur Pharmaceuticals)
• SX600 (SpineThera)
  And many others

Have a look at the sample report: https://www.delveinsight.com/sample-request/chronic-lower-back-pain-clbp-market

Scope of the report

• Geography Covered: United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan
• Study Period: 3-year historical and 11-year forecasted analysis (2017-2030)
• Epidemiology Segmentation: Gender Specific, Age Specific, Severity Specific, Total diagnosed etc.
• Markets Segmentation: By Geographies, By therapies
• Companies Covered: Braeburn Pharmaceuticals, Camurus, Regeneron Pharmaceuticals, Teva Pharmaceutical, Pfizer, Eli Lilly and Company, Mesoblast, Egalet Corporation, Axsome Therapeutics, Allodynic Therapeutics, Astellas Pharma, Grünenthal GmbH, Frontier Biotechnologies, DiscGenics, Yuhan Corporation, Semnur Pharmaceuticals, Sollis Therapeutics, SpineThera, Stayble Therapeutics, AnGes MG, Asahi Kasei Pharma, and others.
• Comparative Analysis: Comparative and conjoint analysis of emerging therapies.
• Case Studies
• KOL's Views

Request a WebEx walkthrough of the report: https://www.delveinsight.com/sample-request/chronic-lower-back-pain-clbp-market

Reason to purchase

• Bespoke primary and secondary research
• 24*7 post-sale customer support
• Option for customizing and personalizing research reports as per needs

DelveInsight's Chronic Lower Back Pain (CLBP) Market Insights, Epidemiology and Market Forecast–2030' report proffers an in-depth understanding of Chronic Lower Back Pain, its etiology, and manifestations, a detailed analysis of the disease historical as well as forecasted epidemiology trends, its prevalence, incidence and patient pool. The report covers the comprehensive layout of the available marketed or approved therapies for CLBP and the upcoming therapies in the pipeline in the Chronic Lower Back Pain market with unmet needs, market drivers and barriers that may impact the growth of the market size in the next decade in the 7MM (the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan). Moreover, the Chronic Lower Back Pain Market Insights report lays in front the therapy that has the potential to occupy the significant chunk of the CLBP market, competitors' analysis, key collaborations, licensing opportunities, R&D scenario and significant non-profit organizations working for CLBP patients' relief. 

Table of Contents

Request for a virtual demo.: https://www.delveinsight.com/sample-request/chronic-lower-back-pain-clbp-market and Get in touch for customizable solutions.

Related Reports:

Chronic Lower Back Pain (CLBP) - Epidemiology Forecast to 2030

DelveInsight's 'Chronic Lower Back Pain - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Chronic Lower Back Pain epidemiology in the 7MM.

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance. 
Get a hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact us:
Shruti Thakur
info@delveinsight.com
+91-9650213330